An exploratory study of host polymorphisms in genes that clinically characterize breast cancer tumors and pretreatment cognitive performance in breast cancer survivors

Koleck, Theresa A.; Bender, Catherine M.; Clark, Beth Z.; Ryan, Christopher M.; Ghotkar, Puja; Brufsky, Adam; McAuliffe, Priscilla F.; Sereika, Susan M.; Conley, Yvette P.

doi:10.2147/bctt.s123785

Cited by 18 publications

(20 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Six focused on breast cancer (BC) patients [19][20][21][22][23][24], one reported on both BC and lymphoma patients [25], and three reported on other patient groups [26][27][28]. The remaining seven studies reported results from studies investigating other genes than APOE, e.g., COMT [24,29] and BDNF [14,24], with five of these studies focusing on BC patients [14,[29][30][31][32], one on prostate cancer patients [33], and one on patients with mixed non-CNS cancers [34]. See Table 2 for overview of genotypes and patients.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…Using the NIH Quality Assessment Tool [18], each study received a quality rating (range: 0-14). Eight studies [14,19,20,23,[25][26][27]33] were rated 'good quality' (>9 criteria met), and the remaining nine studies [21,22,24,[28][29][30][31][32]34] were rated 'fair quality' (5-9 criteria met). Study quality ratings are shown in Supplementary Table S3.…”

Section: Study Quality Assessment Of Included Studiesmentioning

confidence: 99%

“…Two studies investigated other genes. A cross-sectional study of newly diagnosed BC patients revealed that all but three out of 25 genes related to BC phenotypes were significantly associated with at least one of eight cognitive factors by either a main effect and/or an interaction effect between genotype and prescribed treatment [31]. Another study investigated 353 SNPs previously found to be associated with cognitive impairment, depression, fatigue or circadian rhythm as possible moderators of prospectively assessed CRCI in prostate cancer patients [33].…”

Section: Other Genesmentioning

confidence: 99%

“…Finally, G homozygous for the minor allele of rs873601 inERCC5 had increased odds of belonging to the low visual working memory trajectory subgroup (i.e., low and improving) (OR Continued. With the exception of CMC2, MMP11, and RACGAP1, all genes were associated with at least one cognitive factor by either a main effect and/or an interaction effect between genotype and prescribed treatment (see[31] for data) Continued.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Genetic risk factors for cancer-related cognitive impairment: a systematic review

et al. 2019

View full text Add to dashboard Cite

Background: Cancer-related cognitive impairment (CRCI) is a commonly reported complaint among non-CNS cancer patients. Even subtle CRCI may have detrimental effects on quality of life and identifying patients at increased risk for CRCI to improve survivorship care is important. In the present paper, we systematically reviewed available studies of possible genetic risk factors for developing CRCI. Methods: Keyword-based systematic searches were undertaken on 24 July 2018 in PubMed, Web of Science, The Cochrane Library, and CINAHL. Three authors independently evaluated full-texts of identified papers and excluded studies with registration of reasons. Seventeen studies reporting results from 14 independent samples were included for review. Two authors independently quality assessed the included studies. The review was preregistered with PROSPERO (CRD42018107689). Results: Ten studies investigated apolipoprotein E (APOE), with four studies reporting that carrying at least one risk allele (APOE4 (e4)) was associated with CRCI, while six studies found no association. The remaining identified genetic risk variants associated with CRCI located in: COMT, four DNA repair genes, five oxidative stress genes, 22 genes related to breast cancer phenotype, and GNB3. No associations were found between CRCI and genes coding for interleukin-6 (IL6), tumor necrosis factor alpha (TNF), interleukin 1 beta (IL1B), and brain-derived neurotropic factor (BDNF). With the exception of APOE, the genetic risk factors had only been investigated in one or two studies each. Conclusions: Overall, the available evidence of possible genetic risk factors for CRCI is limited. While some research suggests a role for the e4 allele, the literature is generally inconsistent, and the currently available evidence does not allow clear-cut conclusions regarding the role of genetic factors in the development of CRCI. Larger genetic studies and studies investigating additional genetic variants are needed to uncover genetic risk factors for CRCI.

show abstract

Section: Study Characteristicsmentioning

confidence: 99%

Section: Study Quality Assessment Of Included Studiesmentioning

confidence: 99%

Section: Other Genesmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Genetic risk factors for cancer-related cognitive impairment: a systematic review

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The role of ORC3 has not yet been documented in tumors. However, a single nucleotide polymorphism of ORC6 was reported as a breast cancer-related candidate gene [66]. Xi et al found that ORC6 was highly expressed in tumors compared to paired normal tissues in colorectal cancer [67].…”

Section: Discussionmentioning

confidence: 99%

Novel candidate biomarkers of origin recognition complex 1, 5 and 6 for survival surveillance in patients with hepatocellular carcinoma

Wang¹,

Wang²,

Huang³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) has high morbidity and mortality and lacks effective biomarkers for early diagnosis and survival surveillance. Origin recognition complex (ORC), consisting of ORC1-6 isoforms, was examined to assess the potential significance of ORC isoforms for HCC prognosis. Methods: Oncomine and Gene Expression Profiling Interactive Analysis (GEPIA) databases were used to examine differential isoform expression, stage-specific expression, calculate Pearson correlations and perform survival analysis. A human protein atlas database was utilized to evaluate the protein expression of ORCs in liver tissue. The cBioPortal database was used to assess isoform mutations and the survival significance of ORCs in HCC. Cytoscape software was employed to construct gene ontologies, metabolic pathways and gene-gene interaction networks. Results: Differential expression analysis indicated that ORC1 and ORC3-6 were highly expressed in tumor tissues in the Oncomine and GEPIA databases, while ORC2 was not. All the ORCs were showed positive and statistically significant correlations with each other (all P<0.001). ORC1-2 and ORC4-6 expressions were associated with disease stages I-IV (all P<0.05), but ORC3 was not. Survival analysis found that ORC1 and ORC4-6 expressions were associated with overall survival (OS), and ORC1-3 and ORC5-6 expression were associated with recurrence-free survival (RFS; all P<0.05). In addition, low expression of these ORC genes consistently indicated better prognosis compared with high expression. Protein expression analysis revealed that ORC1 and ORC3-6 were expressed in normal liver tissues, whereas ORC2 was not. Enrichment analysis indicated that ORCs were associated with DNA metabolic process, sequence-specific DNA binding and were involved in DNA replication, cell cycle, E2F-enabled inhibition of pre-replication complex formation and G1/S transition. Conclusions: Differentially expressed ORC1, 5 and 6 are candidate biomarkers for survival prediction and recurrence surveillance in HCC.

show abstract

Genetic Modulation of Neurocognitive Development in Cancer Patients throughout the Lifespan: a Systematic Review

et al. 2019

View full text Add to dashboard Cite

An exploratory study of host polymorphisms in genes that clinically characterize breast cancer tumors and pretreatment cognitive performance in breast cancer survivors

Cited by 18 publications

References 76 publications

Genetic risk factors for cancer-related cognitive impairment: a systematic review

Genetic risk factors for cancer-related cognitive impairment: a systematic review

Novel candidate biomarkers of origin recognition complex 1, 5 and 6 for survival surveillance in patients with hepatocellular carcinoma

Genetic Modulation of Neurocognitive Development in Cancer Patients throughout the Lifespan: a Systematic Review

Contact Info

Product

Resources

About